Bharat Biotech: Covaxin showed 81% efficacy in phase 3 trials

Hyderabad-based Bharat Biotech on Wednesday announced phase 3 clinical results of its indigenously-made Covid-19 vaccine candidate, Covaxin.

Covaxin, one of two Covid vaccines to have been cleared for emergency use approval by the government, demonstrated an interim clinical efficacy of 81% against novel coronavirus, Bharat Biotech said.

The data come from 25,800 participants who received a vaccine in a 1:1 ratio and showed that the vaccine candidate was well tolerated, the company stated.

The trials were conducted in partnership with the Indian government's medical research body ICMR.

The company further stated that 'the clinical trial will continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints'.

Also Read: Government allows hospitals to administer Covid vaccine 24x7